Abstracts for the Philadelphia ACS Meeting Available for Download

Abstracts for the upcoming Philadelphia ACS meeting are available on the Division web site. Follow the link below to download the MEDI abstracts for the San Diego ACS meeting:

www.acsmedchem.org/?nd=nationalmeetings

Quick Reference Guide to Services

Division Web Site: www.acsmedchem.org
Division Hall of Fame: www.acsmedchem.org/?nd=hof
Division Awards and Prizes: www.acsmedchem.org/?nd=awards
Link to Division Newsletter Archive: www.acsmedchem.org/?nd=newsletters
Link to Archived MEDI Meeting Abstracts: www.acsmedchem.org/?nd=nationalmeetings

ACS Web Page
portal.acs.org

Journal of Medicinal Chemistry
pubs.acs.org/journal/jmcmar

2016 Executive Committee Members

2016 Chair: Thomas Bannister
2015-2016 Program Chair: Wendy B. Young
2016 Vice-Chair: Andrew W. Stamford
Industrial Councilor 2016-18: Amy Ripka
Industrial Councilor 2015-17: William J. Greenlee
Academic Councilor 2014-16: Jane Aldrich
Academic Councilor 2015-17: Craig W. Lindsley
Secretary/PR Chair 2014-16: D. Eric Walters
Membership & Intl. Chair: Patrick M. Woster
Treasurer 2015-17: David P. Rotella
2016 Past Chair: John E. Macor

Contact information for all Division Officers appears at the end of this Newsletter.

Scientific Program for the 252nd ACS Meeting, Philadelphia (Aug 21-25, 2016)
(ACS Abstract system now closed for this meeting)

SUN AM  Estrogen Receptor Based Therapy
SUN AM  General Oral Session I
SUN PM  The Role of Water in Drug Design
SUN PM  General Oral Session II
SUN EVE  Poster Session I and Social Hour
MON AM  Minor Structural Modifications in Drug Design
MON AM  Small Molecules for Treatment of Lupus
MON AM  Solute Carrier Membrane Transporters
MON PM  Privileged Scaffolds in Drug Design
MON PM  Medical Chemistry of Chemical Biology
MON PM  Nucleic Acid Therapeutics
TUES AM  Gut-specific Drug Targeting
TUES AM  Isosteric Replacement Methods
TUES PM  Awards Session
TUES PM  Modulation of Ubiquitin-Proteasome Pathway
WED AM  Epigenetics
WED AM  General Oral Session III
WED PM  First Time Disclosures
WED PM  General Oral Session IV
WED EVE  Poster Session II

Scientific Program for the 253rd ACS Meeting, San Francisco, CA (Apr 2-6, 2017)
(ACS Abstract system opens soon, maps.acs.org)

SUN AM  Macrocycles and Cyclopeptides
SUN AM  General Oral Session I
SUN PM  Factors Influencing Oral Bioavailability
SUN PM  General Oral Session II
SUN EVE  Poster Session I and Social Hour
MON AM  Allosteric Kinase Ligands & Phosphatase Modulators
MON AM  Residence Time, Not Just Affinity
MON PM  Kinase Inhibitors for Immunoinflammatory Diseases
MON PM  Misfolded Proteins in Neurodegenerative Diseases
TUES AM  Hershberg & Smissman Awards
TUES AM  Antibiotic Drug Discovery
TUES PM  Drug Discovery for ALS
TUES PM  General Oral Session III
WED AM  First Time Disclosures
WED AM  Targeting Epigenetic “Writers” and “Erasers”
WED PM  First Time Disclosures
WED PM  General Oral Session IV
WED EVE  Poster Session II
Amy Newman is Awarded Portoghese Lectureship

The American Chemical Society’s Division of Medicinal Chemistry and the *Journal of Medicinal Chemistry* are pleased to announce that Amy Hauck Newman has been selected as the 2016 recipient of the seventh Philip S. Portoghese Medicinal Chemistry Lectureship. This award is named in honor of Phil Portoghese, the long-standing Editor-in-Chief of the *Journal of Medicinal Chemistry*. The Lectureship is administered jointly by the Editor-in-Chief of the Journal and the ACS Division of Medicinal Chemistry. The objective of the lectureship is to honor the contributions of an individual who has had a major impact on medicinal chemistry research. The award is funded principally by the Journal of Medicinal Chemistry (ACS Publications Division) and the awardee is selected by a committee appointed jointly by the Journal and the Division of Medicinal Chemistry. Dr. Newman will receive the award and give the award address at the 252nd National American Chemical Society Meeting in Philadelphia, PA, on Tuesday, August 23.

Dr. Newman received her doctorate in Medicinal Chemistry from the Medical College of Virginia, Virginia Commonwealth University, under the mentorship of Dr. Richard Glennon. After postdoctoral studies, with Dr. Kenner Rice, at the National Institute on Diabetes, Digestive and Kidney Diseases, National Institutes of Health (NIH), and a brief time at Walter Reed Army Institute of Research, she joined the Intramural Research Program of the National Institute on Drug Abuse (NIDA-IRP), NIH, in 1991. She is currently a Senior Investigator and Chief of the Molecular Targets and Medications Discovery Branch and the Medicinal Chemistry Section. She also serves the NIDA-IRP as Deputy Scientific Director and the Director of its Medication Development Program. She has coauthored more than 240 original articles and reviews on the design, synthesis, and pharmacological evaluation of CNS active agents, with an emphasis on selective ligands for the dopamine and serotonin transporters and dopamine D2-like receptors, as leads toward potential treatment medications for substance use disorders. She is also an inventor on 12 U.S. patents or patent applications. Dr. Newman has received several career awards including the Sato International Memorial Award, the Marian W. Fischman Lectureship Award from the College on Problems of Drug Dependence and the NIDA Director’s Innovation Award.

Congratulations to Dr. Wendy Young, Program Chair!

2015-2016 MEDI Program Chair Wendy Young was recently featured in the ACS video series, *What Chemists Do*. You can see her on YouTube! See her at https://www.youtube.com/watch?v=dg_pziMcqxg
2016 Hall of Fame Inductees Announced

The Division is pleased to announce that five medicinal chemists, William A. Denny, Manoj C. Desai, Marvin J. Miller, Ann E. Weber, and Juerg Zimmermann, will be inducted into the ACS Division of Medicinal Chemistry Hall of Fame at the Philadelphia ACS meeting. The induction ceremony will be held on Tuesday, August 23, 2016, from 5:30 - 7:30 p.m., in the Philadelphia Convention Center.

**Bill Denny** received his M.Sc. (1st class) in 1967 and his Ph.D. (under the direction of Professor Con Cambie) in 1969, from the University of Auckland. He then went to Oxford University (UK), where he undertook post-doctoral training in the Dyson Perrins Laboratory, working under the direction of Professor Sir Ewart Jones. Bill then returned to New Zealand and joined the Auckland Cancer Society Research Centre (ACSRC) at the University of Auckland as a Senior Research Fellow, working on development of the topo II inhibitor amsacrine, which was FDA-approved in 1984 in a collaboration with Parke-Davis. He is currently Director of the ASRC, and in 2011 he was appointed to a Distinguished Professorship at the University of Auckland. The ACSRC under Bill’s leadership has to date brought a further 12 drugs to clinical trial. He was the recipient of the American Chemical Society’s Division of Medicinal Chemistry Award in 2014. Bill was a co-founding scientist of the start-up companies Proacta Inc and Pathway Therapeutics. He is an author/co-author on 660 publications (including reviews and book chapters) and a co-inventor on 47 issued US patents.

**Manoj Desai** obtained Ph.D. in organic chemistry from the M. S. University of Baroda in 1981 working with Dr. Sukh Dev and then carried out post-doctoral fellowships at Purdue University (Professor Herbert C. Brown) and at Harvard University (Professor Elias J. Corey). He began his professional career in the pharmaceutical industry at Pfizer Inc and Chiron Corporation. In 2003 he was appointed Vice President of medicinal chemistry at Gilead Sciences. His research efforts at Gilead led to the discovery of cobicistat which is one of components of Stribild® that was approved by FDA for the treatment of HIV infection. He is co-inventor on patents of cobicistat and ledipasvir. Cobicistat is a pharmacoehancer devoid of antiviral activity. Ledipasvir is a part of two-drug regimen in Harvoni® for curing Hepatitis C virus. Manoj was the recipient of the American Chemical Society’s Division of Medicinal Chemistry Award in 2016.

**Marvin Miller** received his B.S. degree in chemistry from North Dakota State University, and his Ph.D. degree in Bioorganic Chemistry at Cornell University, working with Prof. G.M. Coudon. Following postdoctoral studies with Henry Rapoport at the University of California-Berkeley, he joined the faculty at the University of Notre Dame, where he is now George and Winifred Clark Chair Professor of Chemistry. He has produced over 300 peer reviewed publications and more than 25 U.S. patents. Miller is internationally recognized as a leader in the design, syntheses and study of new antibiotics, especially β-lactams. His recent work has focused on *Mycobacterium tuberculosis*. He has trained 80 graduate students, 63 postdoctoral associates, and has influenced numerous undergraduates to pursue careers in medicinal chemistry.

**Ann Weber** obtained her B.S. degree in chemistry *summa cum laude* from the University of Notre Dame. She earned her Ph.D. degree from Harvard University, studying synthetic organic chemistry in the laboratories of Professor David A. Evans. She is currently an independent consultant, working with both biotech and pharma on all aspects of drug discovery. She retired in November 2015 from Merck & Co, where she was most recently Vice President, Lead Optimization Chemistry at the Kenilworth, NJ and
Boston, MA sites of Merck Research Laboratories (MRL). Her work has led to over 40 development candidates, including JANUVIA® (sitagliptin), a treatment for patients with Type 2 diabetes (T2DM), JANUMET®, a fixed dose combination of sitagliptin and metformin, and MARIZEV® (omarigliptin), a once-weekly treatment for T2DM that was approved in Japan in September 2015. One additional drug candidate, vibegron for the treatment of overactive bladder, is in late stage clinical trials. Dr. Weber is co-inventor on over 35 issued US patents. Her awards include the Robert M. Scarborough Award for Excellence in Medicinal Chemistry from the MEDI Division of ACS.

Juerg Zimmermann started his professional career with an apprenticeship at Ciba-Geigy. In 1981 he received his BSc in chemistry from the Chemical Engineering School Burgdorf. He then moved to ETH Zürich where he received his Ph.D. in Synthetic Organic Chemistry under the direction of Prof. Dr. D. Seebach. Juerg complemented his academic education by 2 postdoctoral studies with Prof. Dr. A. Beckwith (Australia) and Prof. Dr. R. Lown (Canada). In 1991, Juerg joined the Ciba-Geigy Oncology Research team as a medicinal chemist. Pioneering the kinase drug discovery efforts, Juerg synthesized the compound that would ultimately become Gleevec. For his invention of Gleevec and his scientific contributions to drug discovery, Juerg has received numerous awards, including the Swiss Chemical Society Sandmeyer Prize, the American Association for Cancer Research Bruce Cain Memorial Award, the European Federation for Medicinal Chemistry UCB Award for Excellence in Medicinal Chemistry, the Thomas Alva Edison Patent Award, the Heroes of Chemistry Award of the American Chemical Society, and the European Inventor of the Year Award.
Buckley, Ericson win Robert M. Scarborough Awards for Graduate / Post-Graduate Excellence in Medicinal Chemistry

The Division of Medicinal Chemistry is pleased to announce that Dr. Dennis Buckley and Dr. Mark Ericson have been selected as winners of the Robert M. Scarborough Award for Graduate / Post-Graduate Excellence in Medicinal Chemistry.

**Dennis Buckley** received his doctorate in chemistry from Yale University in 2013 under the supervision of Professor Craig Crews. While at Yale, Dennis developed small molecule ligands targeting the interaction between the VHL E3 ligase and its substrate HIF1, and then incorporated these ligands into bifunctional inducers of protein degradation. He then began his postdoctoral work at Dana-Farber Cancer Institute (DFCI), an affiliate of Harvard Medical School under the supervision of Professor James Bradner and joint supervision of Professor Nathanael Gray. While at DFCI, Dennis has worked on the development of small molecule modulators of bromodomain function, including the development of the first-in-class degrader of BET bromodomains, dBET1. Dennis’s current research focuses include protein degradation, protein-protein interactions and epigenetics and chromatin modifiers.

**Mark Ericson** received his B.A. in chemistry from Carleton College in 2006. After spending a year performing dental research in the College of Dentistry at the University of Minnesota under the tutelage of Dr. Daranee Tantbirojn, Mark enrolled in the Medicinal Chemistry program at the University of Iowa. Upon completion of his thesis developing novel chemistries for nonviral nucleic acid delivery with Dr. Kevin Rice, Mark joined the laboratory of Dr. Carrie Haskell-Luevano in the Medicinal Chemistry program at the University of Minnesota in 2013. He has been involved in many structure-activity relationship studies involving novel melanocortin ligands. His current project, supported by an NIH F32 fellowship (DK108402), involves the investigation of truncated agouti-related protein (AGRP) mimetics that are equipotent to AGRP. These truncated analogs are the first small AGRP-derived peptides to possess high activity at the melanocortin-4 receptor, and may be developed into weight-gain therapeutics for negative energy-intake conditions such as cachexia.

The Robert M. Scarborough Graduate/Postgraduate Award for Excellence in Medicinal Chemistry is intended to recognize two current graduate student and/or postdoctoral researchers who have had a leading role in significant scientific discoveries in the field of medicinal chemistry. This award is in memory of Robert M. Scarborough, an accomplished medicinal chemist and inventor of drugs such as Natrecor® and Integrilin®, and is sponsored by Portola Pharmaceuticals, Inc., a cardiovascular company founded by Dr. Scarborough. The awardees will present their research at the Fall national meeting of the American Chemical Society as a part of Division of Medicinal Chemistry programming, where they will receive a commemorative plaque and a $500 honorarium.
Three Students Selected to Receive ACSME DI Predoctoral Fellowships

The Division of Medicinal Chemistry is pleased to announce that three graduate students have been selected to receive 2016-2017 Predoctoral Fellowships. The awards, consisting of a $26,000 stipend, are granted to predoctoral students in their third or fourth year of graduate study. Winners must be engaged in medicinal chemistry research in a Medicinal Chemistry, Pharmaceutical Chemistry, Biochemistry, or Chemistry department listed in the current ACS Directory of Graduate Research. Two of these awards are supported by the Medicinal Chemistry Division of ACS. One of the fellowships is supported through the generosity of Division member Thomas Perun. The awardees for the 2016-2017 academic year are:

Alex Nanna, Scripps Research Institute. Advisors: Christoph Rader and William R. Roush. Alex R. Nanna is currently a graduate student at The Scripps Research Institute (Jupiter, FL) where he is co-mentored by Christoph Rader (Cancer Biology) and William R. Roush (Chemistry). He is working on the development of a new site-specific antibody-drug conjugate (ADC) platform using a reactive lysine. Originally trained as a chemist, Nanna works between two departments where he synthesizes cytotoxic payloads, produces antibody, prepares ADC, and tests his platform in vitro and in vivo.

Jennifer Pace, University of Connecticut. Advisor: Kyle Hadden. Jennifer Pace received a B.A. in biochemistry from Saint Anselm College in Manchester, NH, where under the guidance of Dr. Lisa Bonner she developed dopamine transporter inhibitors. In 2013, Jen joined the laboratory of Dr. Kyle Hadden at the University of Connecticut to pursue a PhD in Pharmaceutical Sciences. Her current research is focused on repurposing the FDA-approved anti-fungal agent, itraconazole, as an anticancer chemotherapeutic.

Brandon Drennen, University of Maryland. Advisor: Steven Fletcher. Brandon Drennen was born in Jefferson City, Missouri in 1992. He acquired his B.S degree in Biological Sciences with Summa Cum Laude honors at the Missouri University of Science and Technology. In 2014, he was accepted into the Pharmaceutical Sciences PhD program at the University of Maryland’s School of Pharmacy, where, under the mentorship of Dr. Steven Fletcher, he has published two first author papers and has co-authored a further two papers. Recently, he was awarded the ACS Medicinal Chemistry Division Fellowship for his work regarding the synthesis of BH3 mimetics to inhibit the oncoproteins Mcl-1 and Bcl-2 while leaving the family member Bcl-xL untouched, whose inhibition causes thrombocytopenia.

ACS Webinar Series on Drug Design and Delivery

Meet with expert chemists from every aspect of the drug discovery process to learn how drugs are designed, screened, tested and more. Join us on the last Thursday of every month for informative presentations, and get the chance to ask your questions.

For more information:  [www.acs.org/content/acs/en/acs-webinars/drug-discovery.html](http://www.acs.org/content/acs/en/acs-webinars/drug-discovery.html)
Dr. David P. Rotella has been selected by the American Chemical Society as an ACS Fellow. David is currently the Margaret and Herman Sokol Professor of Medicinal Chemistry at Montclair State University. He has served the Division of Medicinal Chemistry as an academic councilor, vice chair, program chair, chair and on the long range planning committee, and he is currently the Treasurer of the Division. He is also being recognized for making significant contributions to medicinal chemistry in both academia and industry, including the discovery of novel selective phosphodiesterase 5 inhibitors, treatments for Parkinson’s disease, and modulators of calcium-sensing receptors. The full list of 2016 ACS Fellows can be found at www.acs.org/content/acs/en/funding-and-awards/fellows/list-of-2016-acs-fellows.htm.
The 35th National Medicinal Chemistry Symposium was held June 26-29, 2016, at the historic Palmer House Hotel. This was the 35th in the series that was initiated in 1948. The scientific program for the NMCS featured sessions covering the latest advances in medicinal chemistry. Session topic areas included Pharmacokinetic Concepts and Controversies in Modern Drug Design; Transcription Factors as Drug Targets; Epigenetic Mechanisms of Action in the Treatment of Human Diseases; Challenges and Recent Advances in the Treatment of Neurodegenerative Disorders; Innovation through Collaboration; Drugging the Undruggable; the Medicinal Chemistry Division Award Session; a Poster Session. Shown at right are: Manoj Desai, 2016 Division of Medicinal Chemistry Award winner; Michael Sofia, 2016 IUPAC Richter Prize winner; Thomas Bannister, Chair, MEDI Division.

The program booklet and abstracts are available at www.nmcs.info.

Thanks to our sponsors and exhibitors!

This activity was supported by an educational grant from Celgene Corporation.

The next National Medicinal Chemistry Symposium will be held in 2018, location to be determined.
Call for Nominations: The Bristol-Myers Squibb Smissman Award

This award was established in honor of Professor Edward E. Smissman of the University of Kansas, on the occasion of his untimely death in 1974. The Smissman Award is presented in odd-numbered years by the Division of Medicinal Chemistry at the Spring National Meeting of the American Chemical Society. It is given to a living scientist whose research, teaching or service has had a substantial impact on the intellectual and theoretical development of the field of Medicinal Chemistry. Normally, the award is intended for scientists relatively late in their active scientific careers whereupon a substantial body of creative work is available, and sufficient time has passed to put their work in perspective.

Nominations must include a letter of nomination, up to two seconding letters and a copy of the nominee's most recent curriculum vitae. All materials must be received by September 1, 2016. Nomination packets should be submitted electronically as a single file to the 2016 Division Chair, Dr. Thomas Bannister, Scripps Research Institute-Florida, tbannist@scripps.edu. See www.acsmedchem.org/?nd=smissmanaward for further details.
Call for Nominations: The 2017 Robert M. Scarborough Award for Excellence in Medicinal Chemistry

The Robert M. Scarborough Award for Excellence in Medicinal Chemistry is intended to recognize individuals who have had primary, leading roles in the discovery of novel therapeutic agents or who have otherwise made significant scientific discoveries that enhance the field of medicinal chemistry. This award is in memory of Robert M. Scarborough, an accomplished medicinal chemist and inventor of drugs such as Natrecor® and Integrikin®. The award is sponsored by Portola Pharmaceuticals, Inc., a cardiovascular company founded by Dr. Scarborough. The awardee will present an award address at the Fall national meeting of the American Chemical Society as a part of Division of Medicinal Chemistry programming, and will receive a commemorative plaque and a $5,000 honorarium at the symposium.

Candidate selection criteria include scientists under the age of 50 at the time of nomination. Nominees can be employed in industry, academia, government or a private research foundation and must have documented success in the discovery of pharmaceutical entities and/or a substantial body of significant research contributions in medicinal chemistry. Candidates should have a significant record of productivity as measured by the number and quality of scientific publications and issued patents. Nominees are expected to have demonstrated creativity and insight in medicinal chemistry and/or biology and employ pragmatic, empirical problem solving skills.

A completed nomination package includes the candidate’s curriculum vitae, a primary letter of recommendation from someone very familiar with the nominee’s accomplishments that highlights the candidate’s qualities and accomplishments as outlined above, and at least one seconding letter of nomination. These documents should be sent electronically to the Chair of the Division, Dr. Thomas Bannister (tbannist@scripps.edu) by November 1. For further details, see www.acsmedchem.org/?nd=scarboroughaward
**253rd NATIONAL ACS MEETING**  
San Francisco, CA, April 2-6, 2017

**Abstract Submission**

You are invited to submit an abstract for a research presentation at the 253rd National Meeting of the American Chemical Society, to be held April 2-6, 2017, in San Francisco, CA. All abstracts should be submitted online using the ACS Abstract system, MAPS (**http://maps.acs.org**), which will open soon. **The deadline for abstract submission is not yet posted.** The deadline for abstract submission is also the deadline for submission of travel grant applications, as outlined elsewhere in this Newsletter. The MEDI scientific program and abstracts will be available for download 3-4 weeks prior to the meeting, and their availability will be announced by email. For more information on programming or abstract submission, contact the 2015-2016 Program Chair, Wendy Young (young.wendy@gene.com) or the 2017-2018 Program Chair, Andrew Stamford (andrew.stamford@merck.com).

**Division Travel Grants**

The Division of Medicinal Chemistry makes 14 grants of $600 - $1000 available annually to aid young chemists in presenting papers at the ACS National Meetings. Applicants must be ACS regular or student members, and not have previously received a travel award. Each University department can have only one awardee. **Application deadlines are the same as the abstract deadline for each meeting.** In order of priority, the following individuals will be considered for awards: Graduate Student, Postdoctoral Fellow, individual with less than five years post-Ph.D. experience. The scientific merit of the paper to be presented will also be considered. Applications are to be submitted online at the ACS Med Chem website:

**www.acsmedchem.org/?nd=travelgrants**

Awardees will be notified in sufficient time so that they can pre-register for the meeting. **All travel grant recipients are required to acknowledge the Division in a slide or on their poster as a condition of accepting the award.** Awards are made at the Division business meeting, which is held at each national meeting immediately before the Sunday night poster session and mixer. Address info and a complete application appears on the website.

**Chemical Computing Group Grad Student Awards**

Up to two $1,150 Chemical Computing Group Research Excellence Student Travel Award Stipends are available for the **ACS National Meeting in Philadelphia**. The CCG Research Excellence Awards in Medicinal Chemistry have been created to stimulate graduate student participation in ACS MEDI Division activities (symposia and poster sessions) at ACS National Meetings. Those eligible for a CCG Excellence Award are graduate students in good standing, attending a recognized University within the Americas (North, South and Central), who present work within the MEDI program, either in oral or poster format, that include a computational chemistry component. Winners receive $1,150 to offset their travel expenses, as well as a copy of CCG’s MOE (Molecular Operating Environment) software with a one-year license. They are also honored during a ceremony at the MEDI Division's Sunday evening Poster Session. **For details, go to**

**www.acsmedchem.org/?nd=ccgawards**
Sponsorship for Division of Medicinal Chemistry Symposia

Division of Medicinal Chemistry symposia at National Meetings are presented in part through the financial support of sponsor companies. Sponsorship opportunities are available for all upcoming Division of Medicinal Chemistry Symposia. Symposium sponsors for national ACS meetings are acknowledged with a prominent sign outside the meeting room, and by session chairs during the symposium. In addition, a table is provided where company representatives can interact with meeting attendees, and provide promotional materials. For more information on symposium sponsorship, contact the 2017 Program Chair, Andrew Stamford (andrew.stamford@merck.com), or the 2016 Division Chair, Thomas Bannister (tbannist@scripps.edu).

The Division would like to thank the generous sponsors of our Philadelphia symposia!

ACS Publications (Journal of Medicinal Chemistry and ACS Med Chem Letters)
- Amgen
- Bristol-Myers Squibb
- Celgene
- EMD Serono
- Genentech
- Johnson & Johnson
- Lab Networks
- Merck
- MilliporeSigma
- Paraza Pharma
- Pfizer
- Vertex
- WuXi AppTec

MEDI Division Predoctoral Fellowships

The ACS Division of Medicinal Chemistry announces the continuation of its Predoctoral Fellowship program. We anticipate that several $26,000 fellowships will be awarded in 2016. The awards are for predoctoral students in their third or fourth year of graduate study (second or third year of graduate study at the time of application) engaged in medicinal chemistry research in a Medicinal Chemistry, Pharmaceutical Chemistry, Biochemistry, or Chemistry department listed in the current ACS Directory of Graduate Research. Mentors for all applicants must be members in good standing of the Division of Medicinal Chemistry. Funds used to support predoctoral fellowships are to be used solely for stipend support for the awardee.

Nominations should be submitted by the applicant’s Ph.D. advisor and should include a complete student curriculum vitae, including education and work experience; a student bibliography, including reprints of articles; a complete project description including rationale prepared by the candidate (five-page limit); transcripts of all post-high school work, including Graduate Record Examination scores (if available); three letters, including a nomination letter from the student's research advisor; and a letter from a university official with a commitment to cover tuition and all fees granted to other regular graduate students. **Nominations should be submitted to the Past Chair by March 1.**

For details, see 
[www.acsmedchem.org/?nd=predocfellowship](http://www.acsmedchem.org/?nd=predocfellowship)
Invitation to Authors: Journal of Medicinal Chemistry Perspective Series

The Perspective series of the Journal of Medicinal Chemistry is designed to provide an enlightened appraisal of a field of research in which experts review the state-of-the-art for a given area or therapeutic target. Authors have editorial freedom to express their views on the strategic directions of the field of research. The Perspective series provides a forum with high visibility within the pharmaceutical industry and academia. We would like to identify a wide range of potential topics and authors to ensure that a Perspective article is published in every issue of the Journal. We would like the series to be useful to a broad range of scientists interested in the design, discovery and development of novel medicines. We invite you to submit an idea for a Perspective, along with a brief outline of what you will cover in the manuscript. We also welcome your input regarding potential topics of interest and authors for Perspective manuscripts. Please direct correspondence or calls regarding the series to:

William J. Greenlee  
MedChem Discovery Consulting  
115 Herrick Avenue  
Teaneck, NJ 07666-4106  
Phone (908)-463-5332  
william@william-greenlee.com

Advertise in the ACSMEDI Newsletter

The ACSMEDI Newsletter is distributed twice a year to 10,500 medicinal and organic chemist members, and is freely accessible to all through the ACSMEDI homepage. In response to a number of inquiries, we have established the following advertising policy:

- Full page: $900.00
- One-half page: $500.00
- One-quarter page: $350.00

To place an ad or obtain more information, contact the editor at eric.walters@rosalindfranklin.edu

Division Archives Available On-line

Division newsletters, scientific programs and abstract books dating to 2002 are archived online. These documents can be downloaded in pdf format through the Division WWW page:

http://www.acsmedchem.org
1. Regular Executive Committee Members

**Chair 2015**

[Image of Thomas Bannister]

Thomas Bannister Ph.D.
Scripps Research Institute-Florida
130 Scripps Way
Jupiter, FL 33458
(561) 228-2206
tbannist@scripps.edu

**Vice Chair 2016**

[Image of Andrew W. Stamford]

Andrew W. Stamford, Ph.D.
Merck Research Laboratories
RY800-A330
126 E Lincoln Ave
Rahway, NJ 07065
732-594-1960
andrew.stamford@merck.com

**Program Chair 2015-2016**

[Image of Wendy B. Young]

Wendy B. Young, Ph.D.
Director, Medicinal Chemistry
Genentech Inc.
1 DNA Way
MS#18
South San Francisco, CA 94080
Phone: 650-467-7945
young.wendy@gene.com

**Secretary & Public Relations 2014-2016**

[Image of D. Eric Walters]

D. Eric Walters, Ph.D.
Department of Pharmaceutical Sciences
Rosalind Franklin University
3333 Green Bay Road
North Chicago, IL 60064
(847) 578-8613
eric.walters@rosalindfranklin.edu

**Membership & International Relationships**

[Image of Patrick M. Woster]

Patrick M. Woster, Ph.D.
Dept of Drug Discovery & Biomed.
Medical Univ. of South Carolina
70 President St., Room 405
Charleston, SC 29425
843-876-2453
woster@musc.edu

**Treasurer 2015-2017**

[Image of David P. Rotella]

David P. Rotella, Ph.D.
Department of Chemistry & Biochemistry
355 Richardson Hall
Montclair State University
Montclair NJ 07043
(973) 655-7204
rotellad@mail.montclair.edu
Academic Councilor 2014-2016

Jane Aldrich, Ph.D.
Department of Medicinal Chemistry
College of Pharmacy
University of Florida
P.O. Box 100485
Gainesville, FL 32610-0485
352-273-7714
jaldrich@cop.ufl.edu

Academic Councilor 2015-2017

Craig W. Lindsley, Ph.D. (2012-2014)
Pharmacology – Center for Neuroscience
Drug Discovery
12415D MRB IV (Langford)
Vanderbilt University Medical Center
Nashville, TN 37232-0697
(615)-322-8700
craig.lindsley@vanderbilt.edu

Industrial Councilor 2016-2018

Amy Ripka, Ph.D.
WuXi AppTec
(617) 459-8815
Amy.Ripka@wuxiapptec.com

Industrial Councilor 2015-2017

William J. Greenlee, Ph.D.
MedChem Discovery Consulting, LLC
115 Herrick Avenue
Teaneck, NJ 07666-4106
(908) 463-5332
william@william-greenlee.com

Past Chair 2016

John E. Macor, Ph.D.
Bristol-Myers Squibb
P.O. Box 4000, L12-06
Princeton, NJ 08543
(609) 252-7792
john.macor@bms.com
2. Alternate Councilors & Other Ad Hoc EC Members

**Academic Alternate Councilor 2014-2016**

Kenneth A. Jacobson, Ph.D.
NIDDK, National Institutes of Health
Building 8A, Room B1A19
8 Center Dr.
Bethesda, MD  20814
kajacobs@helix.nih.gov

**Academic Alternate Councilor 2015-2017**

Carrie Haskell-Luevano
University of Minnesota College of Pharmacy 8-102 Weaver Densford Hall
308 Harvard Street SE
Minneapolis, MN  55455
(612) 626-9262
chaskell@umn.edu

**Industrial Alternate Councilor 2015-2017**

Amjad Ali, Ph.D.
Merck Research Laboratories
126 E. Lincoln Ave.
Rahway, NJ  07065
(732) 594 8549
amjad_ali@merck.com

**Journal of Medicinal Chemistry Liaison 2016**

Gunda Georg, Ph.D.
Department of Medicinal Chemistry
Editor, *Journal of Medicinal Chemistry*
717 Delaware Street SE
College of Pharmacy University of
Minnesota Minneapolis, MN 55414
(612)-626-6320
goerg@umn.edu

**Industrial Alternate Councilor 2016-2018**

Maria S. Blanco, Ph.D.
Lilly Corporate Center DC1920
Indianapolis, IN  46285
317-433-3612
blanco_maria@lilly.com


Editor-in-Chief, *Annual Reports in Medicinal Chemistry* (2012-2016)

Manoj Desai, Ph.D.
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
(650) 522-5075
manoj.desai@gilead.com

Foreign Societies Liaison 2016

Thomas J. Perun, Ph.D.
Affiliated Scientific
47731 Old Houston Hwy
Hempstead, TX 77445
tjperun@aol.com

Long Range Planning Committee 2015

LRPC Chair 2016

Andrew W. Stamford, Ph.D.
Merck Research Laboratories
RY800-A330
126 E Lincoln Ave
Rahway, NJ 07065
732-594-1960
andrew.stamford@merck.com

The University of Toledo
Dept of Medicinal and Biological Chemistry
MS#606
2801 W. Bancroft St.
Toledo, OH 43606
419.530.1940
amanda.bryant-friedrich@utoledo.edu

Room 336, John G. Rangos, Sr., Building,
855 N. Wolfe Street, Baltimore, MD 21205
410-955-0894
Jbarrow@jhmi.edu

Genentech
Senior Scientist
1 DNA Way
South San Francisco, CA 94090
schwarz.jacob@gene.com
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place
New York, NY 10029-6574
212-241-0363
robert.devita@mssm.edu

Matthew LaMarche, Ph.D. (2014-2016)
Senior Investigator
Medicinal Chemistry
Novartis Institutes for BioMedical Research, Inc.
250 Massachusetts Avenue
Cambridge, MA 02139
Phone (617) 871-7729
matthew.lamarche@novartis.com

Scott P. Runyon Ph.D. (2014-2016)
Director of Organic and Medicinal Chemistry
Research Triangle Institute
3040 Cornwallis Road
RTP, NC 27709
Phone: (919) 316-3842
srunyon@rti.org

Margaret Chu-Moyer, PhD (2014-2016)
Executive Director Research & Site Head,
Amgen Massachusetts
360 Binney Street
Cambridge, MA 02142
Phone: (617) 444-5400
chumoyer@amgen.com

Brian S. J. Blagg, Ph.D. (2014-2016)
Professor of Medicinal Chemistry
University of Kansas
1251 Wescoe Hall Drive, Malott 4070
Lawrence, KS 66045-7562
Phone (785) 864-2288
bblagg@ku.edu

Steven J. Taylor, Ph.D. (2014-2016)
Director, Medicinal Chemistry
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT 06877-0368
Phone (203) 791-6371
steven.taylor@boehringer-ingelheim.com
Paul M. Scola Ph.D. (2014-2016)
Senior Principle Scientist
Bristol Myers Squibb Pharmaceutical Institute
5 Research Parkway
Wallingford, CT 06492
Phone (203) 677-7870
Paul.Scola@bms.com

Lori Gavrin, Ph.D. (2016-2018)
GlaxoSmithKline
Office UP 1E/1510; Mailstop UP1110
1250 S. Collegeville Rd.
Collegeville, PA 19426
(610) 917-4459
lori.k.gavrin@gsk.com

Gregory D. Cuny, Ph.D. (2016-2018)
University of Houston
College of Pharmacy
Science and Research Building 2
3455 Cullen Blvd., Rm 549A
Houston, TX 77204-5037
713-743-1274
gdcuny@central.uh.edu

Sr. Director, Chemistry
Celgene Corp
10300 Campus Point Drive
Suite 100
San Diego, CA 92121
kleftheris@celgene.com

Paul Ornstein, Ph.D. (2016-2018)
Associate Professor of Medicinal Chemistry
College of Pharmacy, Roosevelt University
1400 N. Roosevelt Blvd., Schaumburg, IL 60173
Phone: 847-330-4504
plornstein@roosevelt.edu